Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC), a Montreal-based biotechnology company developing precision oncology therapeutics using its proprietary Accum® technology, has appointed finance executive Sherry Aulin to its Board of Directors. Aulin, who served as Chief Financial Officer of Xenon Pharmaceuticals for over a decade, will also join the company's Audit Committee. The appointment comes alongside a grant of 400,000 incentive stock options, signalling the company's intent to strengthen its capital markets capabilities at what management describes as a significant inflection point.

Key Points

  • Defence Therapeutics Inc. (CSE: DTC, OTCQB: DTCFF, FSE: DTC) is a publicly traded biotechnology company focused on next-generation precision oncology
  • Sherry Aulin has been appointed to the Board of Directors and will serve on the Audit Committee
  • Aulin brings more than 20 years of public company and capital markets experience, including leading over US$1 billion in equity raises at Xenon Pharmaceuticals
  • Investors may watch how Aulin's capital markets expertise influences Defence's financing strategy and corporate development activities

Aulin's Capital Markets Track Record at Xenon Pharmaceuticals

Sherry Aulin most recently served as Chief Financial Officer of Xenon Pharmaceuticals (NASDAQ: XENE), a neuroscience-focused biopharmaceutical company, where she worked for over a decade. During her tenure, the release states she played a key role in the company's Nasdaq IPO, shaped corporate strategy, and led financing activities that raised more than US$1 billion in equity capital. Earlier in her career, she held senior roles at KPMG LLP, serving publicly traded companies across multiple industries, including life sciences. She holds a Bachelor of Commerce from the University of British Columbia and is a Chartered Professional Accountant, Chartered Accountant.

Stock Option Grant Terms Tied to Aulin's Board Appointment

In connection with the appointment, Defence Therapeutics has granted Aulin 400,000 incentive stock options exercisable at $0.40 per share for a period of five years, in accordance with the company's omnibus incentive plan. Of these options, 200,000 are vested immediately, while the remaining 200,000 will vest on the first anniversary of the grant date. The release does not provide additional commentary on the implications of the option grant for existing shareholders beyond the standard terms disclosed.

Accum® Platform Remains Central to Defence's Oncology Strategy

Defence Therapeutics describes itself as committed to making cancer treatment more effective and safer through its Accum® precision drug delivery platform. The company states its technology is designed to enhance the potency of antibody-drug conjugates and other complex biologics at lower doses, with the goal of reducing side effects and improving patient access to advanced therapies. The company pursues collaborations with pharmaceutical and biotechnology partners as part of its development approach. The immediate share price impact of this board appointment was not clear from available public information.